Caladrius Biosciences Inc... (CLBS)
Caladrius Biosciences Statistics
Share Statistics
Caladrius Biosciences has 7.86M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 7.86M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.51M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.47 and the forward PE ratio is null. Caladrius Biosciences's PEG ratio is 0.
| PE Ratio | -0.47 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.14 |
| P/FCF Ratio | -0.58 |
| PEG Ratio | 0 |
Enterprise Valuation
Caladrius Biosciences has an Enterprise Value (EV) of -81.98M.
| EV / Sales | 0 |
| EV / EBITDA | 2.83 |
| EV / EBIT | 3.69 |
| EV / FCF | 3.68 |
Financial Position
The company has a current ratio of 21, with a Debt / Equity ratio of 0.
| Current Ratio | 21 |
| Quick Ratio | 21 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -29.85% and Return on Invested Capital is -29.85%.
| Return on Equity | -29.85% |
| Return on Assets | -28.31% |
| Return on Invested Capital | -29.85% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.02M |
| Employee Count | 27 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.51M |
| Effective Tax Rate | 5.2% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.91, so Caladrius Biosciences's price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 28.42 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -29.05M |
| Operating Income | -28.97M |
| Net Income | -27.47M |
| EBITDA | -28.92M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.78 |
Balance Sheet
The company has 94.97M in cash and 0 in debt, giving a net cash position of 94.97M.
| Cash & Cash Equivalents | 94.97M |
| Total Debt | 0 |
| Net Cash | 94.97M |
| Retained Earnings | -453.02M |
| Total Assets | 85.88M |
| Working Capital | 71.59M |
Cash Flow
In the last 12 months, operating cash flow was -22.25M and capital expenditures -60K, giving a free cash flow of -22.3M.
| Operating Cash Flow | -22.25M |
| Capital Expenditures | -60K |
| Free Cash Flow | -22.3M |
| FCF Per Share | -1.44 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLBS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -211.37% |
| FCF Yield | -171.65% |
Analyst Forecast
Currently there are no analyst rating for CLBS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Sep 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -5.6 |
| Piotroski F-Score | 2 |